Analiz final ki soti nan Faz Pivotal 3 Esè Terapi Jenetik HOPE-B: Efikasite Eta Stab ak Sekirite Etranacogene Dezaparvovec nan Adilt ak Emofili B grav oswa modere grav.
Pwen esansyèl nan 15yèm Kongrè Anyèl EAHAD la

Analiz final ki soti nan Faz Pivotal 3 Esè Terapi Jenetik HOPE-B: Efikasite Eta Stab ak Sekirite Etranacogene Dezaparvovec nan Adilt ak Emofili B grav oswa modere grav.

Wolfgang Miesbach1; Frank WGLeebeek2; Michael Recht3; Nigel S. Key4; Susan Lattimore3; Giancarlo Castaman5; Michael Coppens6; David Cooper7; Sergio Slawka7; Stephanie Verweij7; Robert Gut7; Ricardo Dolmetsch7; Yanyan Li8; Pòl E. Monahan8; Steven W. Pipe9

Envestigatè HOPE-B1; Inivèsite lopital Frankfurt, Frankfurt, Almay2; Erasmus MC, University Medical Center Rotterdam, Netherlands3; Oregon Health & Science University, Portland, OR, Etazini4; University of North Carolina, Chapel Hill, NC, Etazini5; Sant pou maladi senyen ak koagulasyon, Careggi University Hospital, Florence, Itali6; Amstèdam University Medical Centers, University of Amstèdam, Amstèdam, Netherlands7; uniQureBV, Amstèdam, Netherlands/uniQure Inc. Lexington, MA, USA8; CSL Behring, Wa Lapris, PA, Etazini9; University of Michigan, Ann Arbor, MI, Etazini

RELATED kontni

Webinars entèaktif
Imaj

Please enable the javascript to submit this form

Sipòte pa sibvansyon edikasyon bay Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, ak uniQure, Inc.

Esansyèl SSL